ULTRATAG (kit for the preparation of technetium tc 99m red blood cells) by Curium Pharma is clinical pharmacology in vitro tc 99m red blood cell labeling is accomplished by adding 1. First approved in 1991.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
ULTRATAG is an in vitro kit for preparing technetium Tc 99m-labeled autologous red blood cells, a radiopharmaceutical used for gamma scintigraphic imaging of the blood pool. The kit uses a stannous ion-mediated reduction process to bind radioactive technetium to patient red blood cells, achieving ≥95% labeling efficiency within 20 minutes. It is administered intravenously for diagnostic imaging with a biological half-life of approximately 29 hours in the blood pool.
This legacy diagnostic product faces imminent loss of exclusivity with moderate competitive pressure (30%), likely requiring defensive positioning and operational efficiency focus rather than growth investment.
CLINICAL PHARMACOLOGY In vitro Tc 99m red blood cell labeling is accomplished by adding 1.0 to 3.0 milliliters of autologous whole blood, anticoagulated with heparin or Anticoagulant Citrate Dextrose Solution (ACD), to the reaction vial. A portion of the stannous ion in the reaction vial diffuses…
Worked on ULTRATAG at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ULTRATAG offers career exposure to legacy product management, regulatory maintenance, and operational efficiency in a mature diagnostic asset facing competitive and LOE pressures. This role is best suited for professionals seeking to develop defensive commercial strategy and cost-optimization expertise rather than launch or growth-stage experience.